摘要
心血管疾病的生物标志物是诊断、治疗和评估预后不可缺少的一种工具,可溶性ST2是心肌细胞应激和纤维化的标志物,用于对患有多种心血管疾病的患者进行风险分层,是心力衰竭患者临床评估中利尿钠肽的补充,可为治疗提供帮助。住院患者降低利尿钠肽水平可作为出院后发生心力衰竭风险的评估,但出院时的较高水平仍预示着结果更差。除了利尿钠肽之外,可溶性ST2已被证明可为患者评估预后,其浓度的变化和最终浓度都能独立地预测患者的结果。
Cardiovascular disease biomarkers are an indispensable tool for diagnosis,treatment and prognosis.Soluble ST2 is a marker of cardiomyocyte stress and fibrosis,and is used to risk stratification of patients with multiple cardiovascular diseases.It is a supplement to natriuretic peptide in clinical evaluation of patients with heart failure and can help with treatment.Lowering natriuretic peptide levels in hospitalized patients can be used as an assessment of the risk of heart failure after discharge,but regardless of the reduction,higher levels at discharge still indicate worse outcomes.In addition to natriuretic peptides,soluble ST2 has been shown to assess prognosis for patients,and its changes in concentration and final concentrations independently predict patient outcomes.
作者
王同霞
陈章荣
WANG Tongxia;CHEN Zhangrong(Dali University Graduate School,Dali 671000,Yunnan,China;Department of Cardiology,The First Affiliated Hospital of Dali University,Dali 671000,Yunnan,China)
出处
《心血管病学进展》
CAS
2020年第5期495-498,共4页
Advances in Cardiovascular Diseases
基金
国家自然科学基金(81960085)。
